Navigation Links
Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland
Date:5/11/2011

ROCKVILLE, Md., May 11, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has been named Biotechnology Firm of the Year by the Tech Council of Maryland (TCM), the largest technology trade group serving the advanced technology and biotechnology communities of Maryland.  Novavax was recognized as the firm that best exemplifies the spirit of the Maryland biotechnology community and for its presence and leadership in Maryland.

The criteria for selection as biotechnology firm of the year include achieving significant and measurable success, contributing to the advancement of biosciences through cutting-edge research and development, executing a successful growth strategy, and helping to foster a vibrant biotech community.

Stanley Erck, President and Chief Executive Officer of Novavax, stated:  "We are honored to be recognized by the Tech Council of Maryland for our work to develop innovative vaccines to prevent the spread of infectious diseases worldwide.  We have made substantial clinical and corporate progress in the past year and are now in a very strong position to pursue the development of vaccines derived from our unique virus-like particle technology.  My colleagues and I are particularly grateful to the Maryland biotechnology community, including state and county officials, for their strong support of our efforts."

About Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV).  The company's proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide.  The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.  Additional information about Novavax is available on the company's website: www.novavax.com.

Forward Looking Statements

Statements herein relating to Novavax and its ongoing development of its VLP vaccine products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2010, and filed with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax to Report First Quarter 2011 Financial Results on May 9, 2011
2. NOVAVAX Announces Release Date of 2010 Year-End Financial Results and Investor Conference Call
3. NOVAVAX to Present at BIT Life Sciences 3rd World Congress of Vaccine
4. Maryland Governor Martin OMalley to Visit Novavax in Celebration of HHS-BARDA Contract Award
5. NOVAVAX to Present at Citi 2011 Global Health Care Conference
6. NOVAVAX to Present at 13th Annual BIO CEO & Investor Conference
7. NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
8. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
9. NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit
10. NOVAVAX Elects Richard H. Douglas to its Board of Directors
11. Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... CA (PRWEB) , ... May 20, 2017 , ... ... tool that helps avoid the lengthy trial and error process by finding the ... It can also strengthen the doctor-patient relationship through a personalized approach to ...
(Date:5/18/2017)... ... , ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio ... CSM has doubled in size over the past six months with the acquisition of ... Gasper joins CSM as Chief Financial Officer. Roger has over 25 years of ...
(Date:5/18/2017)... (PRWEB) , ... May 17, 2017 , ... ... and equipment for varying industries, including food and dairy, munitions, and pharmaceutical/biotech, recently ... operator safety and ease of use. The improvement in technology comes on the ...
(Date:5/16/2017)... ... May 16, 2017 , ... ... availability of its new ProxiMeta™ Hi-C metagenomic deconvolution service. ProxiMeta enables researchers ... or high-molecular-weight DNA extraction—speeding research insights at lower cost. , “We’re very ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):